This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo

This study has been completed.
Information provided by (Responsible Party):
VIVUS, Inc. Identifier:
First received: June 7, 2012
Last updated: June 12, 2012
Last verified: June 2012
The objective of this study is to evaluate the hemodynamic response to a sublingual dose of glyceryl trinitrate in subjects receiving oral TA-1790, sildenafil citrate, and placebo.

Condition Intervention Phase
Erectile Dysfunction Drug: TA-1790 Drug: Sildenafil citrate Drug: Placebo Drug: Nitrostat Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Crossover Evaluation of the Hemodynamic Response to Sublingual Glyceryl Trinitrate in Patients Receiving TA-1790, Sildenafil, and Placebo

Resource links provided by NLM:

Further study details as provided by VIVUS, Inc.:

Primary Outcome Measures:
  • Change in hemodynamic measurements [ Time Frame: Pre-dose, 5 min interval for first 45 minutes. 60, 90, and 120 minutes post-dose. ]
    Change in hemodynamic measurements consisted of blood pressure and pulse rate measurements.

Enrollment: 106
Study Start Date: March 2004
Study Completion Date: May 2004
Primary Completion Date: May 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment A
TA-1790 + glyceryl trinitrate
Drug: TA-1790
2 TA-1790 100 mg capsules
Drug: Nitrostat
glyceryl trinitrate tablet, USP 0.4 mg
Active Comparator: Treatment B
sildenafil citrate + glyceryl trinitrate
Drug: Sildenafil citrate
2 sildenafil citrate 50 mg capsules
Drug: Nitrostat
glyceryl trinitrate tablet, USP 0.4 mg
Placebo Comparator: Treatment C
placebo + glyceryl trinitrate
Drug: Placebo
2 placebo capsules for TA-1790 100 mg capsules
Drug: Nitrostat
glyceryl trinitrate tablet, USP 0.4 mg


Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Provide written informed consent
  • Willing to comply with all study requirements and clinic schedules
  • Male between 30 to 60 years of age
  • Non-smoker
  • No history of alcohol abuse
  • Normal screening laboratory values

Exclusion Criteria:

  • Allergy or hypersensitive to PDE5 inhibitors
  • Evidence of clinically significant disease
  • Supine systolic/diastolic blood pressure level
  • History of cardiovascular disease
  • Previously participated in TA-1790 within the past 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01616485

United States, Arizona
MDS Pharma Services
Phoenix, Arizona, United States
Sponsors and Collaborators
Study Director: Craig Peterson, MS VIVUS, Inc.
  More Information

Responsible Party: VIVUS, Inc. Identifier: NCT01616485     History of Changes
Other Study ID Numbers: TA-04
Study First Received: June 7, 2012
Last Updated: June 12, 2012

Additional relevant MeSH terms:
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Citric Acid
Sildenafil Citrate
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Urological Agents processed this record on September 21, 2017